Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Lsu Health Sciences Center
mi
from
New Orleans, LA
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Lsu Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Maryland Medical Center
mi
from
Baltimore, MD
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Winthrop University Hospital
mi
from
Mineola, NY
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Legacy Health System
mi
from
Portland, OR
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Legacy Health System
mi
from
Portland, OR
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Temple University Hospital
mi
from
Philadelphia, PA
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Allegheny General Hospital
mi
from
Pittsburgh, PA
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Rhode Island Hospital
mi
from
Providence, RI
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Lexington Pulmonary and Critical Care
mi
from
Lexington, SC
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Lexington Pulmonary and Critical Care
mi
from
Lexington, SC
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
UT Southwestern Medical Center Heart Lung and Vascular Center
mi
from
Dallas, TX
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
UT Southwestern Medical Center Heart Lung and Vascular Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Texas Medical School
mi
from
Houston, TX
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Texas Medical School
mi
from
Houston, TX
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Central Utah Clinic
mi
from
American Fork, UT
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Central Utah Clinic
mi
from
American Fork, UT
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Intermountain Medical Center
mi
from
Murray, UT
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Virginia
mi
from
Charlottesville, VA
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Sentara Hospitals T/A Sentara Cardiovascular Research Institute
mi
from
Norfolk, VA
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Sentara Hospitals T/A Sentara Cardiovascular Research Institute
mi
from
Norfolk, VA
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Spokane Respiratory Consultants
mi
from
Spokane, WA
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Spokane Respiratory Consultants
mi
from
Spokane, WA
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
UW Hospital and Clinics
mi
from
Madison, WI
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
UW Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Comprehensive Cardiovascular Care LLP
mi
from
Milwaukee, WI
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Comprehensive Cardiovascular Care LLP
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
LKH Universitatsklinikum Graz
mi
from
Graz,
Iloprost Power 15 in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
LKH Universitatsklinikum Graz
mi
from
Graz,
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Little Rock, AR
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
San Diego, CA
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Atlanta, GA
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Dalton, GA
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Dalton, GA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Lewiston, ID
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Lewiston, ID
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Park Ridge, IL
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Louisville, KY
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Hattiesburg, MS
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Jackson, MS
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Jackson, MS
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Hackensack, NJ
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis
mi
from
New York, NY
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Columbus, OH
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Toledo, OH
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis
mi
from
Portland, OR
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis
mi
from
Portland, OR
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis
mi
from
Pittsburgh, PA
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigational Site
mi
from
Charleston, SC
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Amarillo, TX
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Amarillo, TX
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Seattle, WA
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Charleston, WV
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Charleston, WV
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  9/15/2015
Novartis Investigative Site
mi
from
Brussel,
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 9/15/2015
Novartis Investigative Site
mi
from
Brussel,
Click here to add this to my saved trials
CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes
CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes
Status: Enrolling
Updated:  9/15/2015
Reliant Medical Group
mi
from
Worcester, MA
CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes
CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes
Status: Enrolling
Updated: 9/15/2015
Reliant Medical Group
mi
from
Worcester, MA
Click here to add this to my saved trials